---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-286957"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2026-06-29T13:00:16+00:00"
generated_at: "2026-06-29T13:01:14.602810+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics appoints Eric Hyllengren as CFO effective July 13, 2026

## Summary
- Eric Hyllengren joins as CFO; previously CFO at Zura Bio, CFO/COO at Atara Biotherapeutics.
- Hyllengren receives $490k base salary, 40% target bonus, option to purchase 1.65M shares.
- SVP Finance Tomohiro Higa to retire in Q3 2026; will remain as consultant for transition.
- CEO Faraz Ali and Tomohiro Higa cease as interim PFO and acting PAO as of July 13.
- Hyllengren brings 20+ years experience in biotech finance, capital markets, corporate strategy.

## SEC filing metadata
- accession: 0001193125-26-286957
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2026-06-29T13:00:16+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000119312526286957/0001193125-26-286957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000119312526286957/tnya-20260629.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-286957
- JSON: https://secwatch.observer/filing/0001193125-26-286957.json
- Plain text: https://secwatch.observer/filing/0001193125-26-286957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.